How should I manage a patient with type 2 diabetes mellitus and chronic kidney disease, selecting glucose‑lowering agents based on estimated glomerular filtration rate and the presence of albuminuria, heart failure, or cardiovascular disease?

Treatment of Diabetes in CKD Patients

First-Line Therapy: Dual Agent Approach

For patients with type 2 diabetes and eGFR ≥30 mL/min/1.73 m², start metformin plus an SGLT2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin) immediately as first-line therapy. 1, 2

Metformin Dosing by Renal Function

• eGFR ≥45 mL/min/1.73 m²: Continue standard metformin dosing up to 2000 mg daily 1, 2
• eGFR 30–44 mL/min/1.73 m²: Reduce metformin to maximum 1000 mg daily and monitor eGFR every 3–6 months 1, 2
• eGFR <30 mL/min/1.73 m²: Discontinue metformin immediately due to lactic acidosis risk 1, 2

SGLT2 Inhibitor Initiation and Continuation

• Initiate SGLT2 inhibitors at standard doses when eGFR ≥30 mL/min/1.73 m²: dapagliflozin 10 mg daily, empagliflozin 10 mg daily, or canagliflozin 100 mg daily 1, 2
• Continue SGLT2 inhibitors even if eGFR subsequently falls below 45 mL/min/1.73 m² because cardiovascular and renal protection persists despite reduced glucose-lowering efficacy 1, 2, 3
• SGLT2 inhibitors reduce cardiovascular death or heart failure hospitalization by 26–29%, kidney disease progression by 39–44%, and all-cause mortality by 31% 2, 4
• Expect a transient eGFR dip of 3–5 mL/min/1.73 m² in the first 1–4 weeks; this is hemodynamic and not harmful 2

---

Second-Line Therapy: GLP-1 Receptor Agonists

When metformin plus SGLT2 inhibitor does not achieve individualized glycemic targets, add a long-acting GLP-1 receptor agonist (semaglutide, dulaglutide, or liraglutide) as the preferred third agent. 1, 2

• GLP-1 receptor agonists require no renal dose adjustment at any eGFR level 2, 5
• They provide cardiovascular event reduction and are especially preferred in patients with established atherosclerotic cardiovascular disease 1, 2
• In advanced CKD (eGFR 15–29 mL/min/1.73 m²), GLP-1 receptor agonists are preferred over insulin because they carry lower hypoglycemia risk, promote weight loss, and provide cardiovascular protection 2

---

Alternative Agents When Preferred Therapies Are Unavailable

DPP-4 Inhibitors

Linagliptin is the preferred DPP-4 inhibitor because it requires no dose adjustment at any eGFR level, including dialysis. 5

• Linagliptin dosing: 5 mg once daily for all patients regardless of eGFR 5

• Sitagliptin dosing by eGFR:

  • eGFR ≥45 mL/min/1.73 m²: 100 mg daily 5
  • eGFR 30–44 mL/min/1.73 m²: 50 mg daily 5
  • eGFR <30 mL/min/1.73 m²: 25 mg daily 5

• DPP-4 inhibitors reduce HbA1c by 0.4–0.9% with minimal hypoglycemia risk 5, 6

• Avoid saxagliptin and alogliptin in patients with heart failure risk due to increased heart failure hospitalization 6

• DPP-4 inhibitors should only be used when SGLT2 inhibitors and GLP-1 receptor agonists are contraindicated, not tolerated, or cost-prohibitive 5

Insulin

• Effective at any eGFR level; dose titrated to clinical response 2
• Initiate when HbA1c >10% or glucose ≥300 mg/dL 2
• Combining insulin with GLP-1 receptor agonist reduces hypoglycemia risk and improves weight outcomes 2

---

Critical Safety Monitoring

• Check eGFR within 1–2 weeks after starting SGLT2 inhibitor, then every 3–6 months if eGFR <60 mL/min/1.73 m² 2
• Measure baseline and follow-up urine albumin-to-creatinine ratio (UACR) every 3–6 months 2
• Do not discontinue SGLT2 inhibitor if eGFR falls below 45 mL/min/1.73 m² after initiation—cardiorenal benefits persist 1, 2

---

Agents to Avoid

Discontinue sulfonylureas (including gliclazide) in all patients with CKD and replace with guideline-directed therapy. 2

• Sulfonylureas do not confer cardiovascular or renal protection compared to SGLT2 inhibitors or GLP-1 receptor agonists 2
• They increase hypoglycemia risk, especially when combined with SGLT2 inhibitors 2
• The 2024 ADA guideline recommends reassessing and discontinuing sulfonylureas when initiating insulin or other glucose-lowering agents 2

---

Lifestyle Modifications

• Recommend at least 150 minutes per week of moderate-intensity physical activity 1, 2
• Advise sodium intake <2 g per day (≈5 g sodium chloride) 2
• Suggest protein intake of approximately 0.8 g per kilogram body weight per day for non-dialysis CKD patients 2

---

Common Pitfalls to Avoid

• Do not use sulfonylureas as alternatives to SGLT2 inhibitors—they lack cardiorenal benefit and increase hypoglycemia risk 2
• Do not withhold SGLT2 inhibitors solely because glucose-lowering efficacy diminishes at eGFR <45 mL/min/1.73 m²—cardiorenal protection remains 1, 2, 3
• Do not combine DPP-4 inhibitors with GLP-1 receptor agonists—no additional clinical benefit 2
• Do not stop metformin abruptly without checking eGFR—verify eGFR is <30 mL/min/1.73 m² before discontinuation 1, 2